SARS-CoV-2 antiviral prescribing gaps among non-hospitalized high-risk adults Journal Article uri icon
Overview
abstract
  • Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

  • Link to Article
    publication date
  • 2024
  • published in
    Research
    keywords
  • COVID-19
  • Coronavirus Infections
  • Drugs and Drug Therapy
  • Hospitalization
  • Physician's Practice Patterns
  • Risk Factors
  • Additional Document Info
    volume
  • 78
  • issue
  • 6